EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

The resilient subset: cancer stem cells at the core of immunotherapy resistance

Julián A Gajón iD, Diego Esperante, Nahuel Ko, Aaron Jimenez-Miranda, Samira Muñoz-Cruz, Ezequiel Fuentes-Panana, Laura C Bonifaz

Immunotherapy Advances · 31.12.2025 · 6 (1)

DOI: 10.1093/immadv/ltag006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunotherapy Advances, online erschienen am 06.05.2026. Verfasst von Julián A Gajón und 6 weiteren Autor:innen. Beteiligte Einrichtung: Posgrado en Ciencias Bioquímicas, Universidad Nacional Autónoma de México, Ciudad de México, México. Die Arbeit nennt 329 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CONAHCyT-PRONACES.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer stem cells (CSCs) are a small subset of cells that possess unique characteristics, including the ability to initiate and sustain tumor growth, self-renew, and differentiate into various types of cancer cells. They play a crucial role in tumor progression, metastasis, and recurrence. In recent years, CSCs have garnered significant attention due to their involvement in therapeutic resistance to both conventional and novel cancer treatments, including immunotherapy. This review delves into the fundamental properties of CSCs, molecular, cellular, and metabolic, focusing particularly on their immunomodulatory effects. We propose a comprehensive model that reflects the involvement of CSCs in various interlinked contexts, including key signaling pathways, the suppressive microenvironment, and the surrounding stromal components. Through this triaxial conceptualization, we highlight the key role of the stemness-orchestrated architecture in contributing to therapeutic failure. We present evidence gathered from diverse clinical settings, demonstrating a tight correlation between a stem tumor phenotype and poor clinical outcomes, including reduced survival rates and dampened response to immune checkpoint inhibitors (ICB). Finally, we propose therapeutic interventions specifically designed to disrupt the architecture of cancer stemness. These include vaccination against CSC antigens, differentiation therapies, cellular therapies, and combinatorial approaches. In summary, this review apprises an integral, up-to-date perspective that redefines the role of CSCs, positioning them at the core of immunotherapeutic resistance.

Schlagwörter

Stichwörter der Autor:innen

cancer signalingcancer stem cellsimmune evasionimmunotherapy resistancetherapeutic failure

Autor:innen und Institutionen

  • Posgrado en Ciencias Bioquímicas, Universidad Nacional Autónoma de México, Ciudad de México, México.
  • Unidad de Investigación Médica en Inmunología, Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
  • Unidad de Investigación Médica en Inmunoquímica, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.
  • Plan de Estudios Combinados en Medicina (PECEM), Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Ciudad de México, México.
  • Unidad de Investigación en Virología y Cáncer, Hospital Infantil de México Federico Gómez, Ciudad de México, México.
  • Coordinación de Investigación en Salud, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México, México.

ORCID-Profile: Julián A Gajón

Förderung

  • CONAHCyT-PRONACES

Zitieren

APA

Gajón, J. A., Esperante, D., Ko, N., Jimenez-Miranda, A., Muñoz-Cruz, S., Fuentes-Panana, E., & Bonifaz, L. C. (2025). The resilient subset: cancer stem cells at the core of immunotherapy resistance. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag006

Vancouver

Gajón JA, Esperante D, Ko N, Jimenez-Miranda A, Muñoz-Cruz S, Fuentes-Panana E, et al. The resilient subset: cancer stem cells at the core of immunotherapy resistance. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag006

BibTeX
@article{Gajn2025,
  author = {Gajón, Julián A and Esperante, Diego and Ko, Nahuel and Jimenez-Miranda, Aaron and Muñoz-Cruz, Samira and Fuentes-Panana, Ezequiel and Bonifaz, Laura C},
  title = {The resilient subset: cancer stem cells at the core of immunotherapy resistance},
  journal = {Immunotherapy Advances},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1093/immadv/ltag006}
}
Kostenlos starten →